EU Expected To Make WTO Move Against Thailand CL Policy
This article was originally published in PharmAsia News
The European Union is expected to seek a World Trade Organization ruling on Thailand's decision to continue its compulsory licensing policy for certain prescription drugs. Germany and France have led an effort to get the EU to act, resulting in a decision to issue a complaint against the practice. The director general of Thailand's Intellectual Property Department said his country would win the WTO case because it has not violated international regulations since it already negotiated prices with makers of other drugs. (Click here for more
You may also be interested in...
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.